Labs Express Concern about Testing Access if FDA Regulates LDTs
Nearly 85% of respondents to an ARUP Labs survey on the impact of the FDA’s proposed rule to regulate LDTs believe it will hurt their labs.
Read MorePosted by Andy Lundin | Mar 5, 2024 | Compliance |
Nearly 85% of respondents to an ARUP Labs survey on the impact of the FDA’s proposed rule to regulate LDTs believe it will hurt their labs.
Read MorePosted by Andy Lundin | Feb 1, 2024 | Diabetes & Metabolic Diseases |
A new study aimed to develop a non-invasive method for early detection of GDM using cell-free DNA (cfDNA) and deep learning models.
Read MorePosted by Andy Lundin | Jan 26, 2024 | Accreditation, Company News |
Babson Diagnostics’ highly-automated microsample laboratory has been awarded accreditation by the College of American Pathologists (CAP).
Read MorePosted by Chris Wolski | Jan 23, 2024 | Compliance |
CLP Editor Chris Wolski examines the need for LDT regulations, and issues an industry-wide call to action.
Read MorePosted by Chris Wolski | Jan 19, 2024 | Middleware & Software |
Low-code LIMS offer an adaptable, nimble platform, facilitating quick customization to cater to the specific, individualized needs of a lab.
Read More